Keywords: glaxo, wellcome, boosted, new, prods, pretax, up

Glaxo Wellcome Boosted By New Prods; Pretax Up 34%

Article | 05 August 1996

Print This

Despite declining revenues from its leading antiulcerant Zantac (ranitidine), Glaxo Wellcome posted sales for the six months to end-June of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in